|Bid||0.451 x 1200|
|Ask||0.470 x 2900|
|Day's Range||0.4500 - 0.4724|
|52 Week Range||0.3700 - 3.2800|
|Beta (3Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
EDISON, N.J., Nov. 27, 2018 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs.
EDISON, N.J., Nov. 06, 2018 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs.
Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today announced the appointments of James R. Neal and James Sapirstein to its board of directors. With more than three decades of life science industry experience each, Mr. Neal and Mr. Sapirstein provide Leading BioSciences with broad expertise in such areas as drug development and commercialization, strategic business operations, financial management and business development transactions. Mr. Neal, who currently serves as chief executive officer and board member for XOMA Corporation (XOMA), has nearly 35 years of life science industry leadership experience. His expertise spans such areas as development and commercialization of novel technologies and products, as well as formation and oversight of successful global business and technology collaborations. In his current role at XOMA, Mr. Neal spearheaded and secured the requisite capital to support a strategic transition of the company’s operations to focus on a royalty monetization model. Prior to XOMA, Mr. Neal served as acting chief executive officer of Entelos, Inc, a leader in bio-simulation technologies, at which he was responsible for partnerships with global pharmaceutical companies such as Eli Lilly and GlaxoSmithKline. He was chief executive officer at Iconix Biosciences at the time it was acquired by Entelos in 2007. While at Iconix, Mr. Neal was credited with establishing multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration. He also previously served as executive vice president of Incyte Genomics, where he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as sales, marketing and business development activities for the company.
ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (“HBV”), today announced that it has completed dosing of the last cohort of healthy subjects for its CRV431 drug-drug interaction (“DDI”) study. The single-dose crossover study evaluated subjects co-treated with Viread® (tenofovir disoproxil fumarate) (“TDF”), an approved treatment for chronic HBV infection. The DDI study is the second stage of CRV431's streamlined early clinical program, which is agreed upon with the U.S. Food and Drug Administration (“FDA”).
ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that the primary endpoints of safety and tolerability were met in a single ascending dose (SAD) study of CRV431 conducted in the United States. Subjects in the study were treated with escalating doses of CRV431 administered as a single dose. In addition to a favorable safety and tolerability profile, pharmacokinetic (PK) profiling demonstrated CRV431 exposure levels that are anticipated to be efficacious in future HBV patient studies. “The positive results from this trial support the continued development of CRV431 in a Phase 2 clinical efficacy study.
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.
Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , July 10, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...
Live Webcast Scheduled for July 12, 2018, 10:00 AM ET, followed by Q&A EDISON, N.J. , July 5, 2018 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on ...